Moberg Pharma Launches Innovative New Kerasal Product in the U.S.

STOCKHOLM--()--Regulatory News:

Moberg Pharma AB (STO:MOB) today announced that it shipped opening orders of its new line extension, Kerasal® Complete Care in Walgreens, the #1 drug chain in the U.S., with additional retailers expected to follow.

Kerasal® Complete Care, a unique new foot care product brings together two highly effective treatments to restore healthy nail appearance and treat toe and foot skin fungus (athlete’s foot) in a convenient dual-pack. Targeted toward the multitudes of consumers who have both damaged nails and toe and foot skin fungus, Kerasal Complete Care includes the market leading Kerasal Nail® Fungal Renewal, clinically proven to improve nail appearance in as little as two weeks and; Kerasal® Toe & Foot Anti-Fungal, a highly effective treatment based on clotrimazole 1%, for foot fungus. Kerasal Complete Care will be sold in approximately 7,000 Walgreens locations in the foot care section beginning in March 2015.

“We are excited to launch our next innovation in foot care. Consistent with our strategic goal to be number one in products related to nail fungus, we continue to seek new product innovations that offer unique, convenient and highly effective solutions for our consumers and retail partners. Until now, there has been no product on the market that addresses both these needs, marketed and promoted as a single convenient solution. Kerasal Complete Care is a dual-pack kit that provides a daily single regimen for addressing both needs”, said Peter Wolpert, CEO of Moberg Pharma AB.

About this information

Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:30 am (CET) on February 13, 2015.

About Moberg Pharma

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®as well as Phase II pipeline assets. Kerasal Nail®(Emtrix®and Nalox™in certain markets outside the U.S.) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by the acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com.

This information was brought to you by Cision http://news.cision.com

Contacts

Moberg Pharma AB
Peter Wolpert, CEO
Phone: +46 (0)70 - 735 71 35
E-mail: peter.wolpert@mobergpharma.se
or
Moberg Pharma AB
Anna Ljung, CFO
Phone: +46 (0)70- 766 60 30
Email: anna.ljung@mobergpharma.se

Contacts

Moberg Pharma AB
Peter Wolpert, CEO
Phone: +46 (0)70 - 735 71 35
E-mail: peter.wolpert@mobergpharma.se
or
Moberg Pharma AB
Anna Ljung, CFO
Phone: +46 (0)70- 766 60 30
Email: anna.ljung@mobergpharma.se